![Erin Foff](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Erin Foff
Hoofd Techniek/Wetenschap/O&O bij
MAPLIGHT THERAPEUTICS, INC.
Vermogen: 4 M $ op 31-07-2026
Profiel
Erin Pennock Foff is currently Chief Medical Officer at MapLight Therapeutics, Inc. since 2021.
Formerly, Dr. Foff was Executive Director-Clinical Development at ACADIA Pharmaceuticals, Inc. Education includes doctorates from Baylor College of Medicine and Sidney Kimmel Medical College.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 17-08-2026 | 312.261 ( 0,59% ) | 4 M $ | 31-07-2026 |
Actieve functies van Erin Foff
| Bedrijven | Functie | Begin |
|---|---|---|
| MAPLIGHT THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-04-2021 |
Eerdere bekende functies van Erin Foff
| Bedrijven | Functie | Einde |
|---|---|---|
| ACADIA PHARMACEUTICALS INC. | Corporate Officer/Principal | - |
Opleiding van Erin Foff
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
15
Eerstegraads connecties
4
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
ACADIA Pharmaceuticals, Inc.
 ACADIA Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals drugs for treatment of central nervous system disorders | Health Technology |
Baylor College of Medicine
 Baylor College of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sidney Kimmel Medical College
 Sidney Kimmel Medical College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
MapLight Therapeutics, Inc.
 MapLight Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops therapeutics for debilitating central nervous system disorders | Health Technology |
